The treatment of metastatic colorectal cancer has changed substantially in the past two decades with the development of more effective chemotherapy protocols and molecular-based strategies. Despite these changes, intravenous fluorouracil chemotherapy remains an important component of treatment for metastatic colorectal cancer, generally combined with leucovorin plus oxaliplatin (FOLFOX) or leucovorin plus irinotecan (FOLFIRI). However, changes to the method of delivery with oral alternatives, such as capecitabine, are being developed to simplify drug delivery.
Original Article: [Comment] Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer
NEXT ARTICLE